Market Cap 21.49B
Revenue (ttm) 2.26B
Net Income (ttm) 858.98M
EPS (ttm) N/A
PE Ratio 8.39
Forward PE 8.16
Profit Margin 37.95%
Debt to Equity Ratio 0.84
Volume 1,746,500
Avg Vol 3,996,042
Day's Range N/A - N/A
Shares Out 583.17M
Stochastic %K 80%
Beta 0.60
Analysts Strong Sell
Price Target $44.14

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Industry: Biotechnology
Sector: Healthcare
Phone: 212 883 0200
Address:
110 East 59th Street, New York, United States
labibaouf
labibaouf Oct. 23 at 11:16 PM
$RPRX soon to break $50
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 17 at 5:34 PM
$SNDX It's disappointing the EMA recommended not approving Rezurock in the EU. The EMA believes its data did not show any clinical benefit. All the same, total Q1 2025 Rezurock sales were $131MM of which $9 came from the EU ($8MM came from ROW). This hurts for Sanofi but is by no means catastrophic. Though unrelated to efficacy by itself, Niktimvo has a completely different MOA than Rezurock. Put simpler, they target the same indication but are otherwise not like drugs. Niktimvo 1st year US sales are otherwise on track to double Rezurock's 1st year sales forecast by Kadmon & provided Sanofi when acquired for $1.9B. SNDX investors should be reminded $RPRX, after we assume was considerable due diligence, invested $350MM for a 13.8% share of Niktimvo's US sales (roughly a $2.6B valuation as a royalty). This is not investment advice. SNDX has a 10/25/25 PDUFA for its flagship Revuforj in mNPM1 leukemias. A CRL could adversely affect valuation
2 · Reply
Doozio
Doozio Oct. 17 at 12:46 PM
$RPRX feels like a wen. Not if situation. 🐒🍌🧠⏰♾️
0 · Reply
JFDI
JFDI Oct. 15 at 1:02 PM
$RPRX Stage 2 cont...
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 4 at 10:21 PM
The attachment compares the projected revenue & EPS multiples of $LGND v. 3 peers $RPRX $XNCR $XOMA that also invest in biopharma royalties. LGND appears to be an amazing company with a great future. We are not bashing LGND. However, simple analytics suggest LGND, up ~80%+ since June 2025, is now over-priced primarily because they trade @ multiples 2X higher than these 3 peers. Of course we could be wrong. This is not investment advice. Shorting a stock like LGND is extremely risky because, in theory, losses are infinite. History suggests LGND might retract after reporting Q3 2025 earnings as valuation opportunity are reset (the $HROW phenomenon in May 2023...but HROW recovered & then some later). LGND also holds equity investments where valuation gains may not manifest in traditional revenues & earnings forecasts. Again, this is not investment advice. Comments? Pushback? Are these 3 not peers?
2 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 3:15 AM
$RPRX: Unusual Options Activity Alerted CALL flow observed 137x contracts at Strike price of $37.5 Exp on 04/17/2026 with Premium of $27K and showing NEUTRAL Sentiment
0 · Reply
IEC_IR
IEC_IR Sep. 29 at 2:17 PM
$RPRX Royalty Pharma appoints Ted Love as lead independent director NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. “I am delighted to welcome Ted to the key role of Lead Independent Director,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. “Ted has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization’s (BIO) Board of Directors. Ted has consistently demonstrated exceptional judgment and leadership, and we look forward to his continued stewardship as we advance our mission to accelerate innovation in life sciences.” “I am honored to be appointed Lead Independent Director,” said Ted. “Royalty Pharma’s pioneering approach to life sciences innovation and its commitment to long-term value creation make it a remarkable organization. I look forward to continuing my contributions to the Board, providing independent oversight and helping to guide the company’s strategic direction.” #IECIR
0 · Reply
SweepCastApp
SweepCastApp Sep. 21 at 6:34 PM
$RPRX: SWEEP CALL flow spotted 🙌 641 @ 1.90, Strike 37.5, Exp 04/17/2026, Premium $121,918, Sentiment BULLISH
0 · Reply
Doozio
Doozio Sep. 13 at 5:07 PM
$RPRX n they tried to go MNDY 🐑 again as the 🧠 flop lands? All them bums been SPOT on tight weekly closes. 🐒🍌🧠⏰♾️
0 · Reply
StevenDegrijse
StevenDegrijse Sep. 8 at 5:38 PM
$RPRX What was that dip (-4%)?
0 · Reply
Latest News on RPRX
Royalty Pharma Declares Fourth Quarter 2025 Dividend

Oct 17, 2025, 8:15 AM EDT - 7 days ago

Royalty Pharma Declares Fourth Quarter 2025 Dividend


Royalty Pharma: Investor Day Upside

Sep 12, 2025, 3:54 PM EDT - 6 weeks ago

Royalty Pharma: Investor Day Upside


Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)

Sep 11, 2025, 8:16 PM EDT - 6 weeks ago

Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)


Royalty Pharma: Keep Delivering, Buy Confirmed

Aug 9, 2025, 6:23 AM EDT - 2 months ago

Royalty Pharma: Keep Delivering, Buy Confirmed


Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:52 PM EDT - 2 months ago

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript


Royalty Pharma Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Royalty Pharma Reports Second Quarter 2025 Results


Royalty Pharma Declares Third Quarter 2025 Dividend

Jul 18, 2025, 8:15 AM EDT - 3 months ago

Royalty Pharma Declares Third Quarter 2025 Dividend


Royalty Pharma Completes the Acquisition of Its External Manager

May 16, 2025, 4:30 PM EDT - 5 months ago

Royalty Pharma Completes the Acquisition of Its External Manager


Royalty Pharma to Present at Upcoming Investor Conferences

May 13, 2025, 8:15 AM EDT - 5 months ago

Royalty Pharma to Present at Upcoming Investor Conferences


Royalty Pharma: Again, Guidance Raised, Buy Confirmed

May 11, 2025, 9:18 PM EDT - 5 months ago

Royalty Pharma: Again, Guidance Raised, Buy Confirmed


Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript

May 8, 2025, 12:44 PM EDT - 6 months ago

Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript


Royalty Pharma Reports First Quarter 2025 Results

May 8, 2025, 7:15 AM EDT - 6 months ago

Royalty Pharma Reports First Quarter 2025 Results


Royalty Pharma Declares Second Quarter 2025 Dividend

Apr 21, 2025, 4:15 PM EDT - 6 months ago

Royalty Pharma Declares Second Quarter 2025 Dividend


Royalty Pharma Announces Upcoming Investor Day

Mar 27, 2025, 8:15 AM EDT - 7 months ago

Royalty Pharma Announces Upcoming Investor Day


17 Upcoming Dividend Increases, Including 3 Kings

Feb 13, 2025, 11:03 AM EST - 9 months ago

17 Upcoming Dividend Increases, Including 3 Kings

ADM AFL BKH CTSH ED FBP J


Royalty Pharma: Delivering Growth With A Positive Story Ahead

Feb 12, 2025, 10:02 PM EST - 9 months ago

Royalty Pharma: Delivering Growth With A Positive Story Ahead


Royalty Pharma Announces R&D Funding Collaboration With Biogen

Feb 12, 2025, 6:30 AM EST - 9 months ago

Royalty Pharma Announces R&D Funding Collaboration With Biogen


Royalty Pharma plc (RPRX) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 1:40 PM EST - 9 months ago

Royalty Pharma plc (RPRX) Q4 2024 Earnings Call Transcript


Royalty Pharma Reports Q4 and Full Year 2024 Results

Feb 11, 2025, 7:15 AM EST - 9 months ago

Royalty Pharma Reports Q4 and Full Year 2024 Results


Royalty Pharma: Key Strategic Updates To Be Priced In

Jan 15, 2025, 3:49 AM EST - 10 months ago

Royalty Pharma: Key Strategic Updates To Be Priced In


Royalty Pharma simplifies corporate structure with $1.1 bln deal

Jan 10, 2025, 7:31 AM EST - 10 months ago

Royalty Pharma simplifies corporate structure with $1.1 bln deal


labibaouf
labibaouf Oct. 23 at 11:16 PM
$RPRX soon to break $50
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 17 at 5:34 PM
$SNDX It's disappointing the EMA recommended not approving Rezurock in the EU. The EMA believes its data did not show any clinical benefit. All the same, total Q1 2025 Rezurock sales were $131MM of which $9 came from the EU ($8MM came from ROW). This hurts for Sanofi but is by no means catastrophic. Though unrelated to efficacy by itself, Niktimvo has a completely different MOA than Rezurock. Put simpler, they target the same indication but are otherwise not like drugs. Niktimvo 1st year US sales are otherwise on track to double Rezurock's 1st year sales forecast by Kadmon & provided Sanofi when acquired for $1.9B. SNDX investors should be reminded $RPRX, after we assume was considerable due diligence, invested $350MM for a 13.8% share of Niktimvo's US sales (roughly a $2.6B valuation as a royalty). This is not investment advice. SNDX has a 10/25/25 PDUFA for its flagship Revuforj in mNPM1 leukemias. A CRL could adversely affect valuation
2 · Reply
Doozio
Doozio Oct. 17 at 12:46 PM
$RPRX feels like a wen. Not if situation. 🐒🍌🧠⏰♾️
0 · Reply
JFDI
JFDI Oct. 15 at 1:02 PM
$RPRX Stage 2 cont...
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 4 at 10:21 PM
The attachment compares the projected revenue & EPS multiples of $LGND v. 3 peers $RPRX $XNCR $XOMA that also invest in biopharma royalties. LGND appears to be an amazing company with a great future. We are not bashing LGND. However, simple analytics suggest LGND, up ~80%+ since June 2025, is now over-priced primarily because they trade @ multiples 2X higher than these 3 peers. Of course we could be wrong. This is not investment advice. Shorting a stock like LGND is extremely risky because, in theory, losses are infinite. History suggests LGND might retract after reporting Q3 2025 earnings as valuation opportunity are reset (the $HROW phenomenon in May 2023...but HROW recovered & then some later). LGND also holds equity investments where valuation gains may not manifest in traditional revenues & earnings forecasts. Again, this is not investment advice. Comments? Pushback? Are these 3 not peers?
2 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 3:15 AM
$RPRX: Unusual Options Activity Alerted CALL flow observed 137x contracts at Strike price of $37.5 Exp on 04/17/2026 with Premium of $27K and showing NEUTRAL Sentiment
0 · Reply
IEC_IR
IEC_IR Sep. 29 at 2:17 PM
$RPRX Royalty Pharma appoints Ted Love as lead independent director NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. “I am delighted to welcome Ted to the key role of Lead Independent Director,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. “Ted has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization’s (BIO) Board of Directors. Ted has consistently demonstrated exceptional judgment and leadership, and we look forward to his continued stewardship as we advance our mission to accelerate innovation in life sciences.” “I am honored to be appointed Lead Independent Director,” said Ted. “Royalty Pharma’s pioneering approach to life sciences innovation and its commitment to long-term value creation make it a remarkable organization. I look forward to continuing my contributions to the Board, providing independent oversight and helping to guide the company’s strategic direction.” #IECIR
0 · Reply
SweepCastApp
SweepCastApp Sep. 21 at 6:34 PM
$RPRX: SWEEP CALL flow spotted 🙌 641 @ 1.90, Strike 37.5, Exp 04/17/2026, Premium $121,918, Sentiment BULLISH
0 · Reply
Doozio
Doozio Sep. 13 at 5:07 PM
$RPRX n they tried to go MNDY 🐑 again as the 🧠 flop lands? All them bums been SPOT on tight weekly closes. 🐒🍌🧠⏰♾️
0 · Reply
StevenDegrijse
StevenDegrijse Sep. 8 at 5:38 PM
$RPRX What was that dip (-4%)?
0 · Reply
eWhispers
eWhispers Aug. 30 at 4:44 PM
The Pharmaceuticals are among the leaders this quarter, with 86% of $IHE outperforming the S&P 500 $SPY since reporting earnings. The only laggards among the group are $PFE $ZTS $RPRX PBH and OGN https://www.earningswhispers.com/wrs
2 · Reply
JFDI
JFDI Aug. 29 at 12:12 PM
$RPRX trend is up
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 25 at 12:35 PM
$RPRX $AMGN Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug https://ooc.bz/l/75050
0 · Reply
smartkarma
smartkarma Aug. 23 at 7:02 AM
$RPRX | Royalty Pharma Eyes China’s Biotech Boom—Can Early Bets Deliver Solid Future Payouts? "Royalty Pharma's recent earnings for the second quarter of 2025 showcased significant progress, underscoring both strengths and areas of potential..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/royalty-pharma-eyes-china-s-biotech-boom-can-early-bets-deliver-solid-future-payouts
0 · Reply
SanKish
SanKish Aug. 11 at 10:34 PM
$RPRX why did it drop 3.7% during the day and 1.3% AH? Someone made enough money and liquidated? But right before divi date?
0 · Reply
clownmarket
clownmarket Aug. 9 at 7:09 PM
I was just looking through some 13Fs and thought this was interesting. $RPRX completely liquidated its equity portfolio during Q2 This may have been a contributing factor toward $BHVN and $BCRX share price weakness during April -> June because RPRX had a material position in both companies.
7 · Reply
sherowcap
sherowcap Aug. 7 at 10:52 AM
$BDX 13x earnings, 2% dividend and spinoff transaction with $WAT will unlock value and allow for big buyback. Another name in Hc too cheap due to the group $BDX $RPRX
0 · Reply
SanKish
SanKish Aug. 7 at 2:33 AM
$RPRX does anyone know why this is down. Haven’t been able to go thru the ER details so if anyone has the info why it is down, please share.
0 · Reply
handsomeCat
handsomeCat Aug. 6 at 1:36 PM
$RPRX surprised this one is down this AM. what gives ? Earnings look pretty good to me, potential double digit growth for a royalty company?
0 · Reply
sherowcap
sherowcap Aug. 6 at 1:14 PM
$RPRX Cheap as can be and just internalized the manager to cut expenses next decade. Margins and cash flow juggernaut- AHs still another 20 bucks higher
0 · Reply
mikesterz7
mikesterz7 Aug. 6 at 11:54 AM
$RPRX Earnings beat!
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 30 at 1:56 PM
While $SNDX partner $INCY reported compelling Niktimvo Q225 sales yesterday morning, SNDX reports Q225 Revuforj sales next week. Because INCY reports Niktimvo sales, SNDX analyst revenue estimates reflect Revuforj only (outside some ex-US Niktimvo royalties). Rezurock non-US sales were not 5% of the US in its 1st 3 years. In Q125, Rezurock ex-US sales were ~16% of US Of the 11 analysts that cover SNDX, 3 provide consistent longer-term peak sales ests north of $1B/year. Attached is a comparison of SNDX 10-year analyst revenue estimates compared to like estimates from 6 SNDX peers whose mgmt (not analysts) projected roughly the same $750 - $1B peak sales profile. All were acquired for $1.7 to $2.2B. If SNDX analyst estimates are credible & if Revuforj is worth a M&A revenue multiple consistent with these 6 peers (2 HUGE IFs) then is it possible Revuforj is worth a like valuation should SNDX exit via M&A? What about Niktimvo ($RPRX)? We'd genuinely appreciate perspectives. $XBI
1 · Reply